GSK has agreed to acquire Canada’s Bellus Health for around $2 billion, bolting on a late-stage drug candidate for chronic refractory cough. The $14.75-per-share deal will add P2X3 antagonist ...
The FDA has issued a complete response letter (CRL) to Merck & Co's gefapixant candidate for refractory chronic cough, delaying the programme and giving Bayer an opportunity to close the gap with its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results